Virtual Library
Start Your Search
- Virtual Library Home
- IASLC Library
- Explore Event
-
WCLC 2022
2022 World Conference on Lung Cancer
As an IASLC member, you can enjoy complimentary access to the presentations from the World Conference on Lung Cancer 2022. If you participated in the conference, kindly utilize the code "WCLC2022ACCESSFULL" to enter the virtual meeting and access the recordings.
Presentation Date(s):- August 6 - 9, 2022
- Total Presentations: 2015
-
+
MA07 - Overcoming Resistance to EGFR Inhibitors
- Type: Mini Oral
- Track: Metastatic Non-small Cell Lung Cancer - Molecular Targeted Treatments
- Presentations: 13
- Moderators:Dana Lucia Stanculeanu
- Coordinates: 8/08/2022, 12:15 - 13:15, Hall C7
-
+
MA07.01 - Session Introduction
12:15 - 12:16 | Author(s): Dana Lucia Stanculeanu
- Abstract
Loading... -
+
MA07.02 - Session Introduction
12:16 - 12:17 | Author(s): Ross Soo
- Abstract
Loading... -
+
MA07.03 - Real-world Landscape of EGFR C797X Mutation as a Resistance Mechanism to Osimertinib in Non-small Cell Lung Cancer
12:17 - 12:22 | Author(s): Suresh S. Ramalingam
- Abstract
Loading... -
+
MA07.04 - Amivantamab and Lazertinib in Combination With Platinum-Based Chemotherapy in Relapsed/Refractory EGFR-mutant NSCLC
12:22 - 12:27 | Author(s): Melina Elpi Marmarelis
- Abstract
Loading... -
+
MA07.05 - Phase 1b/2 Study of Combined HER Inhibition in Refractory EGFR-mutated Metastatic Non-small Cell Lung Cancer (NSCLC)
12:27 - 12:32 | Author(s): Jonathan Goldman
- Abstract
Loading... -
+
MA07.06 - Discussant
12:32 - 12:42 | Author(s): Laura Mezquita
- Abstract
Loading... -
+
MA07.07 - Clinical/Molecular Profile of Patients with Non-small Cell Lung Cancer (NSCLC) with Incidental Pathogenic Germline Variants Detected in cfDNA
12:42 - 12:47 | Author(s): Laura Mezquita
- Abstract
Loading... -
+
MA07.08 - JIN-A02, a Highly Effective 4th Generation EGFR-TKI, Targeting EGFR C797S Triple Mutation in NSCLC
12:47 - 12:52 | Author(s): Mi Ran Yun
- Abstract
Loading... -
+
MA07.09 - BBT-176, a 4th generation EGFR TKI, for Progressed NSCLC after EGFR TKI Therapy: PK, Safety and Efficacy from Phase 1 Study
12:52 - 12:57 | Author(s): Sun Min Lim
- Abstract
Loading... -
+
MA07.10 - Discussant
12:57 - 13:07 | Author(s): Pasi A Janne
- Abstract
Loading... -
+
MA07.11 - Live Q&A
13:07 - 13:15
- Abstract
Loading... -
+
Session Moderator
13:07 - 13:15 | Author(s): Dana Lucia Stanculeanu
- Abstract
Loading... -
+
Session Moderator
13:07 - 13:15 | Author(s): Ross Soo
- Abstract
Loading...